Journal article icon

Journal article

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Abstract:

CONTEXT: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency and male hypogonadism are widely recognized side effects of mitotane treatment. OBJECTIV...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1210/jc.2012-2851

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
Expand authors...
Journal:
Journal of clinical endocrinology and metabolism
Volume:
98
Issue:
1
Pages:
161-171
Publication date:
2013-01-01
DOI:
EISSN:
1945-7197
ISSN:
0021-972X
Source identifiers:
363838

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP